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Abstract
Background: The association between atopic sensitisation, atopic eczema
(AE) and asthma is known, but distinct roles of allergies on long‐term health
are unestablished.
Objective: Evaluation of allergic symptoms and sensitisation in adolescents
who in infancy had AE and verified cows' milk allergy (CMA) or AE and a
negative CMA challenge, and controls.
Methods: Children with AE, with and without CMA, from a randomised con-
trolled study in 1999‐2001 examining the effect of probiotics on AE severity at
older than 12 months of age, attended a follow‐up visit at age 16 to 18, with age‐
matched controls. Data came from a questionnaire (ISAAC questionnaire), ana-
lysis of serum antigen‐specific immunoglobulin Es (IgEs), and clinical evaluation.
Group comparisons were carried out (χ2 tests and logistic regression).
Results: Fifty‐two patients with AE and CMA (AE/CMA+ group), 52 with AE
and suspicion of CMA (AE/CMA− group), and 57 controls attended a study
visit. IgE‐mediated sensitisation was significantly more prevalent in the
AE/CMA+ group vs the controls, for horse, cat, dog, egg white and wheat
(P< .024 for all). For birch, timothy and mugwort (P< .008 for all), sensiti-
sation was more prevalent in both the AE/CMA+ group and the AE/CMA−
group vs controls. On the basis of questionnaire data the AE/CMA+ group
reported a significantly higher lifetime prevalence of wheezing (64% vs 35%
and 32%; P= .001), noninfectious rhinitis (85% vs 62% and 56%; P= .004), and
hay fever (77% vs 52% and 33%; P< .001) vs the AE/CMA− group and the
control group, respectively.
Conclusion and Clinical Relevance: Patients with AE and CMA in infancy,
as opposed to patients with AE only, or controls, report more allergic symp-
toms and exhibit more allergic sensitisation in adolescence. This indicates that
CMA in infancy is an independent risk factor of allergic disease in adolescence.
KEYWORD S
adolescent, allergic rhinitis, asthma, atopic eczema, cows' milk allergy, specific IgE
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd
1 | INTRODUCTION
During recent decades, the prevalence of allergic sensitisation
and diseases in industrialised countries has increased.1 Major
differences in sensitisation patterns exist between countries,
with, for example, cows' milk allergy (CMA) being the most
common food allergy in early childhood in the western
world, affecting 0.5% to 3% of children.2‐4 Studies are, how-
ever, difficult to compare, as diagnostic criteria for CMA
differ. Some investigators base their diagnoses on im-
munoglobulin E (IgE)‐mediated sensitisation, others depend
on open food challenges, while the gold standard for diag-
nosis is the double‐blind, placebo‐controlled food challenge
(DBPCFC),5 which is cumbersome and costly, and hence less
used. No immunological markers can predict the develop-
ment of tolerance accurately. This development, however, is
generally favourable, as the majority of cases of CMA resolve
spontaneously, with the rate and timing of resolution in
studies showing wide variety.4,6 Compared to controls, pa-
tients with atopic eczema (AE) more frequently develop food
allergies (FA). A study found among AE patients with mostly
mild to moderate severity of disease, that the incidence of FA
was 15.9%.7 Several studies have reported a 30% prevalence
of FA among children with AE. These studies, however,
mostly included children with moderate to severe AE.8
Sensitisation to food allergens predispose individuals to
later allergic disease, but specific allergen‐associated risks
are as yet unestablished. One study revealed that sensiti-
sation to hens' eggs or cows' milk at an early age predicted
asthma and rhinoconjunctivitis at 14 years of age, compared
with no sensitisation at an early age. In this study, however,
the effect was particularly attributed to sensitisation to hens'
eggs.9 Allergic symptoms and disease undergo transforma-
tions over time; most early‐life food allergies resolve,
whereas allergic rhinoconjunctivitis and allergic asthma
become more prevalent with age. The timing of IgE‐
mediated sensitisation tends to follow the allergen order of
exposure. In Finland, sensitisation to cows' milk primarily
appears in infants as they are exposed to cows' milk protein
in formula typically from 3 to 5 months of age. Cows' milk
is followed by sensitisation to wheat, fish and egg, still
followed by nuts, as they are introduced later in life, ac-
cording to national recommendations. Food sensitisation is
succeeded by sensitisation to outdoor allergens, primarily
birch, then timothy and mugwort. Sensitisation to indoor
allergens such as furry pets depend on the timing and level
of exposure. Sensitisation to food allergens occurs transcu-
taneously as well as orally, whereas to indoor and outdoor
allergens it occurs mainly via inhalation.10‐12 It is unclear
whether AE and FA are manifestations of the same atopic
disposition or if they represent separate entities that
are independent risk factors of subsequent development of
allergic rhinitis and asthma.13
Most studies on the associations between CMA and
other atopic conditions have been focused on infancy and
early childhood, and only a few have concerned adoles-
cents or adults. One retrospective study on 807 patients
with IgE‐mediated CMA included some patients up to
the age of 23. However, the median age at the first visit
was 13 months, and the median duration of follow‐up
was 54 months. This study revealed a relatively high
prevalence of asthma (49%) and allergic rhinitis (40%) in
the total study population, which could be explained by
the fact that the patients were recruited from a tertiary
care centre.6 Another study, involving 139 CMA patients,
both IgE‐mediated and non–IgE‐mediated, showed
development of asthma in 32%, rhinoconjunctivits in 20%,
and other FAs in 19%. The patients were aged 14 months to
18 years at the end of the study, and the mean follow‐up time
was 7 years.14 The role of CMA as an independent risk factor
of other allergic conditions remains unclear. The aim of this
study was, thus, to assess the implications of early‐life CMA
and AE in adolescence.
2 | METHODS
2.1 | Study population
For this follow‐up study, the participants were from a
randomised controlled study conducted in 1999‐2002
concerning the effect of probiotics on AE.15 In brief,
patients with AE born in 1999‐2001 that had been
referred to a tertiary hospital in connection with a
suspicion of CMA at an age below 12 months were re-
cruited. The mean age of the patients in the original
study was 6.4 months upon entry. The patients were
randomised in a double‐blind manner to receive for
4 weeks either Lactobacillus rhamnosus GG, a mix of four
probiotics (L. rhamnosus GG, L. rhamnosus LC705, Bifi-
dobacterium breve and Propionibacterium freudenreichii
ssp. shermanii JS) or placebo. Among these 230 patients,
120 were diagnosed with CMA on the basis of the results
of a DBPCFC that was performed 4 weeks after the
probiotic intervention. For this follow‐up study recruit-
ment of unselected control patients born in 1999‐2001
was through an advertisement on social media and
distribution of leaflets with information on participation
at upper secondary schools and vocational schools in
Helsinki. Patients were recruited and examined in 2017.
2.2 | Questionnaires
Upon entry the patients answered the first questionnaire.
This questionnaire was designed to assess allergic
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symptoms (wheeze, rhinitis and rash), doctor‐diagnosed
allergic diseases, other primary diseases, contact with
agriculture and pets, use of probiotics, and smoking. The
second questionnaire concerned the living environment,
family, education, diet, and parental medical history.
Assessment of allergic symptoms was based on the Fin-
nish version of the International Study of Asthma and
Allergies in Childhood (ISAAC) Phase Three Core
Questionnaire for children aged 13 to 14 years.16,17 The
primary outcome was the prevalence of allergic symp-
toms. For these analyses the response to the question
“How many attacks of wheezing have you had in the past
12 months?” was dichotomised as either at least one at-
tack or no attacks. The response to the question “In the
past 12 months, have you had a dry cough at night, apart
from cough associated with a cold or chest infection?”
was also dichotomised as either not at all or at least once.
We used combinations of answers from the ISAAC
questionnaire to establish the presence of allergic disease
in the previous 12 months. Affirmative answers to the
following two questions yielded a diagnosis of current
asthma: “Have you had wheezing or whistling in the
chest in the past 12 months?” and “Have you ever had
asthma?”. Furthermore, affirmative answers to the fol-
lowing three questions yielded a diagnosis of current al-
lergic rhinitis: “Have you ever had a problem with
sneezing, or a runny or blocked nose when you DID NOT
have a cold or the flu?”, “In the past 12 months, have you
had a problem with sneezing, or a runny or blocked nose
when you DID NOT have a cold or the flu?” and “In the
past 12 months, has this nose problem been accompanied
by itchy‐watery eyes?”. Affirmative answers to the fol-
lowing three questions yielded a diagnosis of current
eczema: “Have you ever had an itchy rash which was
coming and going for at least 6 months?”, “Have you had
this itchy rash at any time in the past 12 months?” and
“Has this itchy rash at any time affected any of the fol-
lowing places: the folds of the elbows, behind the knees,
in front of the ankles, under the buttocks, or around the
neck, ears or eyes?” Our study is not part of the ISAAC
collaboration.
The presence of doctor‐diagnosed allergic diseases
(food allergy, AE, asthma, rhinoconjunctivitis) was based
on patient reporting. All patients from the original study
were considered to have AE and those diagnosed with
CMA were considered to have food allergy in our
analyses.
2.3 | Laboratory measurements
Blood samples were collected at the study visit. Levels of
IgEs against specific food allergens (egg white, wheat,
milk) and aeroallergens (horse, cat dander, dog dander,
timothy grass, mugwort, birch) were measured by using
ImmunoCAP reagents (Thermo Fisher Scientific Inc.,
Waltham, MA).
2.4 | Clinical evaluation and pulmonary
function testing
Patients that had answered the first questionnaire were
invited to a study visit. At this visit, they signed a written
informed consent document and were examined by a
doctor (SP). The severity of AE was evaluated by using
the SCORAD calculator.18 We performed flow‐volume
spirometry to assess lung function by using Medikro Pro
equipment (Medikro Oy, Kuopio, Finland). Measure-
ments were both pre‐ and post‐bronchodilation, which
was attained by administering salbutamol (0.4 mg). The
following spirometry values were analysed: forced vital
capacity (FVC), forced expiratory volume in one second
(FEV1) and FEV1/FVC. Analysis and reporting of results
were based on percentages of predicted values adjusted
for age, sex and height.
2.5 | Statistical analysis
Categorial variables were compared by using the Pearson
χ2 test. Fisher's exact test was applied when the expected
cell count was below five. Significant associations were
further analysed by using an adjusted logistic regression
model. Continuous variables were analysed by using the
independent samples t test, the Mann‐Whitney U test,
one‐way analysis of variance (ANOVA), analysis of cov-
ariance (ANCOVA) and the Kruskal‐Wallis test.
An exploratory analysis regarding possible con-
founders related to ISAAC questionnaire answers was
performed by using the χ2 test. Analysed factors were sex,
siblings (yes/no), patient's age, body mass index, age of
mother, age of father, the patient's education, smoking,
passive smoking, household pets and use of probiotics
during the past 3 years as well as the past 12 months.
Confounders included in the final model were sex, pets
and passive smoking.
For a separate analysis of original patients only, pos-
sible confounders that were analysed were: sex, siblings,
parental atopy, siblings' atopy, parental smoking, dura-
tion of exclusive breastfeeding, duration of overall
breastfeeding, mode of delivery, sensitisation defined as
positivity of prick tests (egg white, milk, wheat, any)
and/or specific IgEs (milk, wheat), age at introduction of
solids, and original intervention with probiotics. Con-
founders included in the final model were sex, parental
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atopy and sensitisation to any measured allergen. The
results of logistic regression models are presented as odds
ratios and adjusted odds ratios (aOR) with 95% con-
fidence intervals (CIs).
Flow‐volume spirometry was analysed by ANCOVA.
We identified potential covariates on the basis of factors
known to influence spirometry results (flu in the past
2 weeks, cooperation, previous spirometry, age, smoking,
education, height, asthma, rhinoconjunctivitis). Among
them, asthma and cooperation significantly affected our
spirometry values. These covariates were tested in con-
nection with assumptions of normality, linearity, homo-
geneity of variances, homogeneity of regression slopes,
and reliable measurement of the covariate. Only co-
operation qualified as a covariate for FVC and FEV1.
FEV1/FVC was analysed by way of one‐way ANOVA as
no covariates met the above assumptions.
Differences in SCORAD points between groups were
compared by using the Kruskal‐Wallis test, as the data
was not normally distributed.
We analysed IgE‐mediated sensitisation by using two
different cut‐off values: >0.35 and >0.7 kU/L. Differences
between groups were analysed by using the χ2 test.
For all statistical tests significance was set at P< .05.
The data was analysed using SPSS software for Windows,
version 22 (IBM Corp., Armonk, NY). Bonferroni cor-
rection was used to adjust for multiple comparisons.
The study was approved by the ethics committee of
Helsinki University Hospital for Children and Adoles-
cents. The study complies to the STROBE guidelines.
3 | RESULTS
3.1 | Study population
Among 227 patients from the original study, 104 consented
to take part in our follow‐up study (Figure 1). Demographic
characteristics among all three groups were similar, except
for sex, as 84.2% of the control patients were female
(Table 1). There were no significant differences between the
AE/CMA+ and AE/CMA− groups regarding original pro-
biotic intervention, maternal atopy, paternal atopy, bipar-
ental atopy, paternal smoking, maternal smoking during
pregnancy, having pets at the time of the original study, or
mode of delivery. Neither was there a difference within the
AE/CMA+ group regarding CMA diagnosis or sensitisation
to milk (measured by either prick test or s‐IgE) (data not
shown). However, among patients who had a mother that
smoked at the time of the original study, loss to follow‐up
was more common compared with those who did not
(73.5% and 51.3%, respectively). Loss to follow‐up was also
more common in males compared with females (62.2% and
41.9%, respectively).
FIGURE 1 Flowchart of the study
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3.2 | IgE‐mediated sensitisation
The AE/CMA+ group was most frequently sensitised to
all tested allergens, followed by the AE/CMA− group,
and the control group (Table 2). With a cut‐off level of
0.35 kU/L there was a significant difference in sensitisa-
tion between the AE/CMA+ group and the control group
as regards horse (P= .019), cat (P= .003), dog (P= .014),
egg white (P= .024) and wheat (P= .017) allergens, and
for any food‐specific IgE (P= .001), while differences
compared with the AE/CMA− group were not sig-
nificant. For birch (P< .001), timothy (P= .008), for any
inhalant‐specific IgE (P< .001) or for any specific IgE
(P< .001) the differences were significant as regards both
the AE/CMA+ group compared with the control group
and the AE/CMA− group compared with the control
group. However, when the cut‐off level was set at
0.7 kU/L, the AE/CMA+ group was significantly more
sensitised to any food‐specific IgE compared with both the
AE/CMA− group and the controls (P= .003). We conducted
a separate analysis of original patients who were sensitised
as infants (sensitisation defined as either a positive skin
prick test (mean weal diameter ≥3mm, greater than the
negative control) or s‐IgE> 0.35 kU/L for any tested aller-
gen), divided into two groups according to CMA status, to
estimate the effect of CMA while controlling for sensitisa-
tion. In this subanalysis the group sizes were AE/CMA+,
n= 27 and AE/CMA−, n = 22. No significant differences in
sensitisation in adolescence were found when all patients
had been sensitised in infancy.
3.3 | Allergic symptoms based on the
ISAAC questionnaire
On the basis of ISAAC questionnaire data, the AE/CMA+
group reported a significantly higher lifetime prevalence of
wheezing compared with the AE/CMA− group or the con-
trol group (P= .001) (Table 3). The AE/CMA+ group also
reported a significantly higher lifetime prevalence of rhinitis
TABLE 1 Background characteristics
of the study population
AE/CMA+ AE/CMA− Controls
n % n % n % P value
Female 25/52 48.1 25/52 48.1 48/57 84.2 <.001
Mother's age at birth, mean, y 30.6 NA 31.6 NA 30.4 NA .541a
Maternal atopy 8/51 15.7 5/51 9.8 5/56 8.9 .545
Paternal atopy 4/51 7.8 6/51 11.8 7/56 12.5 .808
Any parent atopic 11/51 21.6 9/51 17.6 9/56 16.1 .815
Both parents atopic 1/51 2.0 2/51 3.9 3/56 5.4 .872
Siblings 38/43 88.4 32/35 91.4 47/51 92.2 .866
Age, mean, y 17.2 NA 17.2 NA 17.1 NA .815a
Smoker (current) 4/52 7.7 4/52 7.7 6/57 10.5 .830
Mother smoking (ever) 17/52 32.7 18/52 34.6 16/57 28.1 .754
Father smoking (ever) 16/52 30.8 24/52 46.2 25/57 43.9 .233
Passive smoking (at age 17) 24/52 46.2 30/52 57.7 32/57 56.1 .441
Furry pets (current) 30/52 57.7 29/52 55.8 34/57 59.6 .902
Upper secondary school 34/43 79.1 28/35 80.0 47/51 92.2 .124
Vocational school 9/43 20.9 6/35 17.1 4/51 7.8 .124
Not in school 0/43 0.0 1/35 2.9 0/51 0.0 .124
Probiotics weekly or daily in past
12 mo
11/52 21.2 9/52 17.3 9/57 15.8 .815
Probiotics during last 3 y 35/52 67.3 37/52 71.2 41/57 71.9 .907
Note: Categorial variables analysed by χ2 test. P< .05 indicated in bold.
Abbreviations: AE/CMA+, patients with atopic eczema and confirmed cows’ milk allergy in infancy;
AE/CMA−, patients with atopic eczema and excluded cows’ milk allergy in infancy; ANOVA, analysis of
variance.
aAnalysis with ANOVA.
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compared with both the AE/CMA− group and the control
group (P= .004). Additionally, the AE/CMA+ group re-
ported a significantly higher lifetime prevalence of hay fever
compared with the AE/CMA− group or the control group
(P< .001). Both AE/CMA+ and the AE/CMA− groups re-
ported significantly more “interference of rhinitis with daily
activities in the past 12 months” (moderately or a lot com-
pared with a little or none) compared with the control group
(P= .006). Both groups also reported a significantly higher
lifetime prevalence of an itchy rash (P= .006), and eczema at
any time (P< .001) compared with the control group. In the
AE/CMA+ group, compared with the controls, both ISAAC‐
based current rhinoconjunctivitis (P= .003) and ISAAC‐
based current eczema (P= .003) were significantly more
frequent. Table 3 shows a breakdown of proportions for all
ISAAC questions. We carried out a subanalysis of original
patients who were sensitised during infancy, measured by
PRICK and/or IgE, to further investigate the effect of CMA,
and control for sensitisation. The patients were divided in
two groups according to CMA status; group sizes were
AE/CMA+, n=27 and AE/CMA−, n= 12. There were no
significant differences in reported symptoms. Compared with
the control group, AE with CMA was associated with in-
creased risks of wheezing (aOR, 4.77), rhinitis (aOR, 6.22),
rhinitis symptoms in the past 12 months (aOR, 18.93), hay
fever (aOR, 8.94) and “interference of rhinitis with daily
activities in the past 12 months” (aOR, 9.39) (Table 4). Atopic
eczema with a suspicion of CMA, compared with the control
group, was associated with hay fever (aOR, 2.73) and
“interference of rhinitis with daily activities in the past
12 months” (aOR, 7.65). In the analysis of combined ISAAC
questions, AE with CMA, as well as AE with a suspicion of
CMA were associated with current rhinoconjunctivitis (aOR,
6.00 and 3.42, respectively) and with current eczema (aOR,
6.08 and 2.99, respectively).
Original patients were analysed separately to adjust
for the effect of AE and demographic characteristics
collected only in the original study. This also enabled us
to compare the effect of CMA with the effect of any atopic
sensitisation in infancy. Compared with AE and a sus-
picion of CMA, AE plus CMA was associated with in-
creased risks of wheezing (crude odds ratio [cOR], 2.81,
95% CI, 1.47‐7.32; aOR, 3.80, 95% CI, 1.59‐9.06), rhinitis
(cOR, 3.44, 95% CI, 1.35‐8.78; aOR, 2.90, 95% CI, 1.16‐
7.21) and hay fever (cOR, 3.09; 95% CI, 1.33‐7.18; aOR,
3.32, 95% CI, 1.25‐8.87). Sensitisation in infancy, mea-
sured by PRICK and/or IgE, was significantly associated
with an increased risk of rhinitis (aOR, 4.60; 95% CI, 1.82‐
11.63), but not with wheezing (aOR, 1.00; 95% CI, 0.41‐
2.47) or hay fever (aOR 2.32; 95% CI, 0.89‐6.06).
3.4 | Doctor‐diagnosed allergic disease
Both the AE/CMA+ group and the AE/CMA− group
(compared with the control group) more frequently
TABLE 2 Proportions of sensitisation to food and inhalant allergens
AE/CMA+ (n= 40) AE/CMA− (n = 38) Controls (n = 50)
% % % P value
Horse 47.5 28.9 20.0 .019*
Cat 70.0 52.6 34.0 .003*
Dog 62.5 50.0 32.0 .014*
Birch 80.0 65.8 40.0 <.001**
Mugwort 57.5 44.7 18.0 <.001**
Timothy 65.0 63.2 36.0 .008**
Wheat 37.5 26.3 12.0 .017*
Milk 15.0 2.6 4.0 .107
Egg white 22.5 11.7 4.0 .024*
Any food 50.0 28.9 14.0 .001*
Any inhalant 90.0 73.7 48.0 <.001**
Any 90.0 73.7 48.0 <.001**
Note: Sensitisation was defined as s‐IgE > 0.35 kU/L. Group comparisons by χ2 test. P< .05 indicated in bold.
Abbreviations: AE/CMA+, patients with atopic eczema and confirmed cows’ milk allergy in infancy; AE/CMA−, patients with atopic eczema and excluded
cows' milk allergy in infancy; IgE, immunoglobulin E.
*Significant difference: AE/CMA+ vs control.
**Significant difference: AE/CMA+ vs control and AE/CMA− vs control.
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reported a doctor's diagnosis of rhinoconjunctivitis (50%,
46.2% and 21.1%, respectively). Proportions differed sig-
nificantly between all groups as regards reported food
allergy (100%, 53.8% and 10.5%, respectively). The AE/
CMA+ group showed a significant association with rhi-
noconjunctivitis (aOR 3.21, 95% CI, 1.39‐7.43). Differ-
ences between groups were not significant as regards a
doctor's diagnosis of asthma (26.9%, 17.3% and 12.3%,
respectively).
3.5 | Atopic eczema activity by SCORAD
scores and lung function
The severity of AE measured in terms of SCORAD scores
was highest in the AE/CMA+ group (mean 8.8, median
5.0), second highest in the AE/CMA− group (mean 6.0,
median 0.10) and lowest in the control group (mean 3.87,
median 0.0). The difference between groups was sig-
nificant as regards the AE/CMA+ group compared with
the control group (P= .022). Spirometry results are
shown in Table 5.
3.6 | Natural history of CMA
Among the 52 patients who were diagnosed with CMA in
the original study, 44 had since included cows' milk in
their diet. For seven patients this data was missing.
Thirty patients disclosed the age at which milk had been
reintroduced in their diet. The mean age at this inclusion
was 5.5 years. Five patients had received oral im-
munotherapy for CMA. One patient, who had not re-
ceived oral immunotherapy, reported that their IgE‐
mediated CMA was still ongoing. Among the 45 original
CMA patients whose current allergy status was known,
IgE for cows' milk was measured in 36. With a 0.35 kU/L
cut‐off value, four of 35 who were classified as tolerant
were still sensitised. With a 0.7 kU/L cut‐off value, this
figure was two of 35. The one patient who reported
TABLE 3 Comparison of proportions of allergic symptoms from ISAAC core questionnaire responses
AE/CMA+ AE/CMA− Controls
n % n % n % P value
Wheezing ever 33/52 63.5 18/52 34.6 18/57 31.6 .001*
Wheezing 12 mo 17/33 51.5 11/19 57.9 9/18 50.0 .906
Wheezing attacks 12 mo (4 or more) 8/17 47.1 6/12 50.0 2/9 22.2 .447
Night wheezing 12 mo (ever) 5/17 29.4 3/12 25.0 2/9 22.2 1.000
Limited speaking 12 mo 5/17 29.4 4/12 33.3 2/9 22.2 .905
Asthma ever 14/52 26.9 9/52 17.3 8/57 14.0 .218
Exercise wheezing 12 mo 16/52 30.8 13/52 25.0 10/57 17.5 .279
Night cough 12 mo 12/52 23.1 8/52 15.4 10/57 17.5 .588
Rhinitis ever 44/52 84.6 32/52 61.5 32/57 56.1 .004*
Rhinitis 12 mo 42/44 95.5 28/34 82.4 25/32 78.1 .052
Itchy‐watery eyes with rhinitis 12 mo 28/42 66.7 22/28 78.6 13/25 52.0 .133
Rhinitis interference with daily activities 12 moa 19/42 45.2 10/28 35.7 2/25 8.0 .006**
Hay fever ever 40/52 76.9 27/52 51.9 19/57 33.3 <.001*
Itchy rash ever 38/52 73.1 28/51 54.9 14/57 24.6 <.001**
Itchy rash 12 mo 31/38 81.6 17/28 60.7 11/14 78.6 .169
Itchy rash skin folds ever 25/31 80.6 17/17 100.0 10/11 90.9 .105
Itchy rash cleared 12 mo 17/31 54.8 12/17 70.6 7/11 63.6 .597
Itchy rash kept awake 12 mo (ever) 12/31 38.7 8/17 47.1 6/11 54.5 .647
Eczema ever 43/52 82.7 39/51 76.5 21/57 36.8 <.001**
Abbreviations: AE/CMA+, patients with atopic eczema and confirmed cows' milk allergy in infancy; AE/CMA−, patients with atopic eczema and excluded
cows' milk allergy in infancy; ISAAC, International Study of Asthma and Allergies in Childhood.
aModerate amount or a lot.
*Significant difference: AE/CMA+ vs AE/CMA−, and AE/CMA+ vs controls.
**Significant difference: AE/CMA+ vs controls, and AE/CMA− vs controls.
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ongoing CMA was not sensitised on the basis of either
cut‐off value.
4 | DISCUSSION
In this study we examined sensitisation, allergic symp-
toms, severity of atopic eczema, lung function and diag-
noses of allergic disease in adolescence among patients
that in infancy had AE with and without CMA, and
unselected controls. Allergic sensitisation to the tested
allergens was most frequent in the AE/CMA+ group. The
differences between groups were mainly significant
between the AE/CMA+ group vs the control group, but
at an IgE cut‐off level of 0.7 kU/L a difference between
the AE/CMA+ group compared with the AE/CMA−
group was observed in connection with sensitisation to
any food allergen. Among allergic symptoms the
AE/CMA+ group reported a significantly higher lifetime
prevalence of wheezing, rhinitis and hay fever compared
with patients with infantile eczema only, and controls.
However, the AE/CMA+ group compared with the
AE/CMA− group were not significantly more often
diagnosed with asthma or allergic rhinoconjunctivitis.
Most studies on CMA have been focused on infants
and younger children, whereas studies on adolescents are
TABLE 4 Association between CMA status in infancy and adolescent allergic symptoms from ISAAC core questionnaire responses
Unadjusted OR (95% CI) Adjusted OR* (95% CI)
AE/CMA+ (n= 52) AE/CMA− (n = 52) AE/CMA+ (n= 52) AE/CMA− (n = 52)
Wheezing ever 3.76 (1.70‐8.33) 1.15 (0.52‐2.55) 4.77 (2.01‐11.30) 1.41 (0.60‐3.28)
Rhinitis ever 4.30 (1.72‐10.75) 1.25 (0.58‐2.69) 6.22 (2.25‐17.24) 1.64 (0.71‐3.83)
Rhinitis 12 mo 5.88 (1.13‐30.54) 1.31 (0.39‐4.41) 18.93 (2.53‐141.60) 3.52 (0.72‐17.33)
Rhinitis interference with daily
activities 12 moa
9.50 (1.98‐45.55) 6.39 (1.24‐32.89) 9.39 (1.81‐48.56) 7.65 (1.30‐44.97)
Hay fever ever 6.67 (2.86‐15.57) 2.16 (0.996‐4.68) 8.94 (3.49‐22.90) 2.73 (1.17‐6.36)
Itchy rash ever 8.34 (3.53‐19.70) 3.74 (1.65‐8.47) 11.60 (4.45‐30.21) 4.68 (1.93‐11.35)
Eczema ever 8.19 (3.34‐20.10) 5.57 (2.40‐12.93) 9.13 (3.48‐23.92) 6.14 (2.49‐15.17)
ISAAC‐based current
rhinoconjunctivitis
3.95 (1.73‐9.01) 2.48 (1.09‐5.68) 6.00 (2.40‐15.06) 3.42 (1.39‐8.43)
ISAAC‐based current eczema 4.35 (1.82‐10.42) 2.28 (0.93‐5.59) 6.08 (2.37‐15.63) 2.99 (1.16‐7.72)
Abbreviations: AE/CMA+, patients with atopic eczema and confirmed cows’ milk allergy in infancy; AE/CMA−, patients with atopic eczema and excluded
cows’ milk allergy in infancy; CI, confidence interval; ISSAC, International Study of Asthma and Allergies in Childhood; OR, odds ratio.
a“A moderate amount” or “a lot” compared with “not at all” or “a little”.
*Adjusted for sex, pets, and passive smoking. P< .05 indicated in bold. The control group is the reference group.
TABLE 5 Spirometry results (percentages) in patients with atopic eczema and cows’ milk allergy in infancy, atopic eczema and a
suspicion of cows’ milk allergy in infancy, and controls
AE/CMA+ (n= 42) AE/CMA− (n = 36) Controls (n = 44)
Mean Adjusted mean Mean Adjusted mean Mean Adjusted mean P value
FVC 98.9 98.1 97.7 97.8 94.3 95.1 .209a
FEV1 96.3 95.2 93.4 93.3 90.6 91.7 .270a
FEV1/FVC 88.5 88.2 90.0 .49b
Note: Among 130 spirometry tests performed, 122 were of adequate quality to be included in the analysis. The same parameters were evaluated after
bronchodilation; differences remained nonsignificant (data not shown)
Abbreviations: AE/CMA+, patients with atopic eczema and confirmed cows’ milk allergy in infancy; AE/CMA−, patients with atopic eczema and excluded
cows’ milk allergy in infancy; ANCOVA, analysis of covariance; ANOVA, analysis of variance; FVC, forced vital capacity; FEV1, forced expiratory volume in
one second.
aANCOVA, means adjusted for sex and cooperation.
bANOVA, no covariates met the assumptions for ANCOVA.
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infrequent; thus our study provides novel information. In
our study, the original diagnosis of CMA relied on a
DBPCFC, which is a major strength, as in previous stu-
dies on adolescents and young adults, results based on
sensitisation or open food challenges have been re-
ported.14,19 The use of a standardised, validated ques-
tionnaire for allergic symptoms facilitates comparison
with other studies. A drawback of this study is the un-
equal sex distribution, as it is known that differences in
allergic disease vary between sexes as age increases.20 We
believe the majority of control patients were female, be-
cause most of these patients attended upper secondary
school, where the majority of students are female. Sex
and educational level elevate the likelihood to participate
in scientific studies, which was accentuated in our ado-
lescent population. In addition, allergic diagnoses at
follow‐up were not verified from patient records, but re-
lied on patient reporting only. In some analyses the group
sizes were so small that there may be a risk of a type II
error, which makes it difficult to draw any firm conclu-
sions. It is noteworthy that our group of CMA patients
included both IgE‐mediated and non–IgE‐mediated
allergy.
In our study there was a significant difference in
sensitisation at the cut‐off level 0.35 kU/L between the
AE/CMA+ group and the control group for all tested
allergens, except, interestingly, cows' milk. An explana-
tion could be that sensitisation to cows' milk has usually
declined by the time of adolescence, even in previously
allergic patients.21 A similar difference in sensitisation
patterns has previously been found in a prospective study
from Finland in which 118 children with CMA were
followed up to the age of 8.6 years.22 Sensitisation was
also more frequent in the AE/CMA+ group compared
with the AE/CMA− group for all allergens, though this
difference was not significant. However, we also carried
out an analysis with a cut‐off of 0.7 kU/L, as some pa-
tients with s‐IgE levels below this may not be truly sen-
sitised. In this analysis a significant difference in
sensitisation to any food‐specific IgE was observed be-
tween the AE/CMA+ group and the AE/CMA− group.
Even in adolescence CMA patients are more sensitised to
food allergens than patients with infantile eczema only.
Analysis of the AE/CMA+ group and the AE/CMA−
group that included only patients that were sensitised as
infants showed no difference in current sensitisation. It
may be that the observed difference between the three
groups is thus more attributable to the original IgE sen-
sitisation than CMA itself, but the number of patients in
the subanalysis was too small to draw any firm conclu-
sions. Previous studies support the idea that non–IgE‐
mediated CMA is a benign condition that is not asso-
ciated with an increased risk of atopic diseases.23
We observed that subjects with AE and CMA in in-
fancy, compared with those with AE only, and unselected
controls, had a higher lifetime prevalence of certain al-
lergic symptoms: wheeze, noninfectious rhinitis and hay
fever. For wheeze and noninfectious rhinitis, as well as
rhinitis symptoms in the past 12 months, the associated
aOR was significantly higher in the AE/CMA+ group
compared with controls, but not in the AE/CMA− group
compared with controls. Subjects with infantile AE both
with and without CMA showed an association with
ISAAC‐based diagnosis of current rhinoconjunctivitis
and ISAAC‐based diagnosis of current eczema compared
with controls, and this association seemed stronger in the
AE/CMA+ group. Thus, patients with CMA not only
exhibited more allergic symptoms in adolescence, but the
symptoms were also more severe. We also analysed the
AE/CMA+ group and AE/CMA− group in a separate
regression model, as this allowed us to adjust for con-
founders that had been examined in the original study,
and to examine the effect of any sensitisation compared
with clinical CMA. The odds of wheezing, noninfectious
rhinitis and hay fever were higher in the AE/CMA+
group compared with the AE/CMA− group. This ad-
justed model also showed an association between early
sensitisation and rhinitis, but not hay fever. These results
are somewhat contradictory, which indicates that early
sensitisation, as well as clinical CMA, has a separate in-
fluence on the exhibited atopic phenotype. However, the
sample size was not large enough to draw any firm
conclusions.
Asthma developed more frequently in the AE/CMA+
group than in the AE/CMA− or control group. Even
though this difference was not significant, a higher pre-
valence of asthma in CMA patients vs controls has pre-
viously been observed.22 In our study, lung function did
not differ between patient groups. Another study re-
vealed that children with CMA in infancy, compared
with controls, at an average age of 8.6 years showed more
signs of airway inflammation, expressed as elevated
fractional exhaled NO and more pronounced bronchial
responsiveness to histamine.24 In a recently published
study, it was found that sensitisation to cows' milk, hens'
eggs or peanuts at the ages of 6 and 12 months, was
associated with reduced FEV1 in adolescence, but the
investigators did not analyse the individual effects of se-
parate allergens, and the study was based on sensitisation
and not diagnosed clinical allergy.25
Responses to ISAAC questions on AE (prevalence of
rash ever, eczema ever and current eczema) showed
significant differences in both original patient groups
compared with the controls. This was expected, as AE
was an inclusion criterion in the original study. This
supports the notion that the ISAAC questionnaire was
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efficient in identifying symptoms correctly in our popu-
lation. Despite not reaching statistical significance, in
adolescence, there were more symptoms of eczema in the
AE/CMA+ group than in the AE/CMA− group.
In a previous study, it was reported that among 139
CMA patients there was a tolerance acquisition rate of
54.6% by the age of five and 69% by the age of 15.14
Tolerance acquisition at a young age was similar in our
study, the median age at acquisition being 5.5 years.
However, the rate of acquisition of tolerance by the time
of the follow‐up visit was 97.8% in our study, which was
higher than the previously reported rate in adolescence.
This may be because five patients in our study had re-
ceived oral immunotherapy for CMA. By comparison, in
another study among 39 infants with CMA, the acquisi-
tion of tolerance was 92% at 5 years and 97% at 15 years.2
Before 10 years age, 41% developed asthma, and 31%
rhinoconjunctivitis. This risk was significantly increased
in patients with IgE‐mediated allergy compared to pa-
tients with non–IgE‐mediated allergy. The CMA diag-
nosis in both studies was based on an open food
challenge, and both IgE‐ and non–IgE‐mediated cases
were included. The prevalence of rhinoconjunctivitis in
our study was 50%, which was higher than in the above
two studies and this may be explained by the fact that all
our patients with CMA also had a diagnosis of AE. The
study population affects the rate of acquisition of toler-
ance, which is higher in population based studies com-
pared to studies from tertiary care centres that focus on
patients with suspected or confirmed allergic disease.6,14
Our findings supported the notion that CMA in in-
fancy has implications on allergy‐related morbidity later
in life, and it poses an independent risk of allergic
symptoms, compared with eczema only. A recent study
on single‐nucleotide polymorphism profiles and genetic
predisposition to other diseases in patients with CMA
indicated that there is an overlap in the genetic aetiology
of CMA and asthma, but for CMA and AE, there is not.26
Our clinical results support this finding. To our knowl-
edge, ours may be the first study carried out to compare
patients with CMA and AE with patients with AE only.
ACKNOWLEDGEMENTS
We thank the study participants, research nurse Rhea
Paajanen for her assistance and Nick Bolton for language
editing. This study was supported by the Päivikki and
Sakari Sohlberg Foundation, Finska Läkaresällskapet, the
Finnish Medical Foundation and the Foundation for
Pediatric Research in Finland.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are
available from the corresponding author upon reasonable
request.
ORCID
Sonja Piippo http://orcid.org/0000-0002-5089-0561
REFERENCES
1. Mastrorilli C, Caffarelli C, Hoffmann‐Sommergruber K. Food
allergy and atopic dermatitis: prediction, progression, and
prevention. Pediatr Allergy Immunol. 2017;28(8):831‐840.
2. Høst A, Halken S, Jacobsen HP, Christensen AE, Herskind AM,
Plesner K. Clinical course of cow's milk protein allergy/intolerance
and atopic diseases in childhood. Pediatr Allergy Immunol. 2002;
13(s15):23‐28.
3. Schoemaker AA, Sprikkelman AB, Grimshaw KE, et al. In-
cidence and natural history of challenge‐proven cow's milk
allergy in European children—EuroPrevall birth cohort.
Allergy. 2015;70(8):963‐972.
4. Wood RA, Sicherer SH, Vickery BP, et al. The natural history of
milk allergy in an observational cohort. J Allergy Clin Immunol.
2012;131(3):805‐812, e4.
5. Niggemann B, Beyer K. Diagnosis of food allergy in children:
toward a standardization of food challenge. J Pediatr
Gastroenterol Nutr. 2007;45(4):399‐404.
6. Skripak JM, Matsui EC, Mudd K, Wood RA. The natural his-
tory of IgE‐mediated cow's milk allergy. J Allergy Clin
Immunol. 2007;120(5):1172‐1177.
7. Spergel JM, Boguniewicz M, Schneider L, Hanifin JM,
Paller AS, Eichenfield LF. Food allergy in infants with atopic
dermatitis: limitations of food‐specific IgE measurements.
Pediatrics. 2015;136(6):e1530‐e1538.
8. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;
387(10023):1109‐1122.
9. Christiansen ES, Kjaer HF, Eller E, et al. Early‐life sensitization
to hen's egg predicts asthma and rhinoconjunctivitis at 14 years
of age. Pediatr Allergy Immunol. 2017;28(8):776‐783.
10. Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis
cause food allergy? A systematic review. J Allergy Clin
Immunol. 2016;137(4):1071‐1078.
11. van Wijk F, Knippels L. Initiating mechanisms of food allergy:
oral tolerance versus allergic sensitization. Biomed
Pharmacother. 2006;61(1):8‐20.
12. Lambrecht BN, Hammad H. Allergens and the airway epithe-
lium response: gateway to allergic sensitization. J Allergy Clin
Immunol. 2014;134(3):499‐507.
13. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ,
Abramson MJ. Atopic dermatitis and the atopic march re-
visited. Allergy. 2014;69(1):17‐27.
14. Santos A, Dias A, Pinheiro JA. Predictive factors for the per-
sistence of cow's milk allergy. Pediatr Allergy Immunol. 2010;
21(8):1127‐1134.
15. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the
treatment of atopic eczema/dermatitis syndrome in infants: a
double‐blind placebo‐controlled trial. Allergy. 2005;60(4):
494‐500.
432 | PIIPPO ET AL.
16. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW. The
international study of asthma and allergies in childhood
(ISAAC): Phase three rationale and methods. Intl J Tuberc
Lung Dis. 2005;9(1):10‐16.
17. Pekkanen J, Remes ST, Husman T, et al. Prevalence of asthma
symptoms in video and written questionnaires among children
in four regions of Finland. Eur Respir J. 1997;10(8):1787‐1794.
18. Stalder JF, Taïeb A, Atherton DJ, et al. Severity scoring of
atopic dermatitis: the SCORAD index. Consensus report of the
European Task Force on Atopic Dermatitis. Dermatology. 1993;
186:23‐31.
19. Alduraywish SA, Lodge CJ, Campbell B, et al. The march from
early life food sensitization to allergic disease: a systematic
review and meta‐analyses of birth cohort studies. Allergy. 2016;
71(1):77‐89.
20. Gough H, Grabenhenrich L, Reich A, et al. Allergic multi-
morbidity of asthma, rhinitis and eczema over 20 years in the
German birth cohort MAS. Pediatr Allergy Immunol. 2015;
26(5):431‐437.
21. Alduraywish SA, Lodge CJ, Vicendese D, et al. Sensitization to
milk, egg and peanut from birth to 18 years: a longitudinal
study of a cohort at risk of allergic disease. Pediatr Allergy
Immunol. 2016;27(1):83‐91.
22. Saarinen KM, Pelkonen AS, Mäkelä MJ, Savilahti E. Clinical course
and prognosis of cow's milk allergy are dependent on milk‐specific
IgE status. J Allergy Clin Immunol. 2005;116(4):869‐875.
23. Helin N, Kolho K, Qvist E, Mäkelä M, Merras‐Salmio L. Gas-
trointestinal symptoms of food challenge‐proven non‐IgE cowʼs
milk allergy are dissipated by early school age. J Pediatr
Gastroenterol Nutr. 2018;66(4):598‐602.
24. Malmberg LP, Saarinen KM, Pelkonen AS, Savilahti E,
Mäkelä MJ. Cow's milk allergy as a predictor of bronchial hy-
perresponsiveness and airway inflammation at school age. Clin
Exp Allergy. 2010;40(10):1491‐1497.
25. Alduraywish S, Luzak A, Lodge C, et al. The role of early life
food sensitization in adolescent lung function: results from 2
birth cohort studies. J Allergy Clin Immunol: In Pract. 2019;
7(6):1825‐1834.e12.
26. Jansen PR, Petrus N, Venema A, et al. Higher polygenetic
predisposition for asthma in cow's milk allergic children.
Nutrients. 2018;10(11):1582.
SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section.
How to cite this article: Piippo S, Viljanen M,
Savilahti E, Kuitunen M. Allergic symptoms and
sensitisation in adolescents with cows' milk allergy
and atopic eczema in infancy. Immun Inflamm Dis.
2020;8:423–433. https://doi.org/10.1002/iid3.324
PIIPPO ET AL. | 433
